Dec 09, 2022 / 01:00AM GMT
Operator
Thank you very much for joining our R&D meeting out of a very busy schedule. I'm delighted to serve as (inaudible) from Corporate Advocacy and Relations. Thank you for your time. You can join this meeting via Zoom Webinar or live streaming.
After our explanation, we will go into Q&A session. You can ask questions only through Zoom Webinar. You cannot ask questions in our live streaming. Today, we have simultaneous interpreting between Japanese and English. If you're joining from Zoom Webinar, from the Zoom screen menu, you can choose the language of your preference.
We're going to explain based on the meeting materials posted on our website. Today's presenters are as follows: Representative Director, President and CEO, Kenji Yasukawa; Chief Scientific Officer, Yoshitsugu Shitaka; Head of Targeted Protein Degradation, Masahiko Hayakawa. During the Q&A session, Primary Focus Lead, Peter Sandor is going to join.
Simultaneous interpreting is available, including Q&A, but we cannot guarantee its accuracy. And this material or presentation by representatives for the
Astellas Pharma Inc R&D Briefing Transcript
Dec 09, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers